de novo foundry ApS
CVR 38734164 · Private limited company (ApS) · Active · Low risk
de novo foundry ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 9 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 16.7m and a net result of DKK -11.5m.
Bankruptcy risk for de novo foundry ApS
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 38734164
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (9 years)
- Address
- c/o Symbion, Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n. (749990)
Bankruptcies in the industry: Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n. - Share capital
- DKK 500k
- Employees
- 4 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 9 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 72.4% |
| Current ratio | 362% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK 4.6m | DKK 8.7m | DKK 2.9m |
| Net profit | DKK -11.5m | DKK -7.0m | DKK -11.2m |
| Equity | DKK 16.7m | DKK 18.2m | DKK 10.3m |
| Total assets | DKK 23.1m | DKK 22.8m | DKK 14.6m |
| Cash | DKK 13.6m | DKK 14.0m | – |
| Short-term debt | DKK 6.4m | DKK 4.5m | – |
| Avg. employees | 12 | 14 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 142 | ||
| 1 Jan 2024 – 31 Dec 2024 | 155 | ||
| 1 Jan 2023 – 31 Dec 2023 | 96 | ||
| 1 Jan 2022 – 31 Dec 2022 | 128 | ||
| 1 Jan 2021 – 31 Dec 2021 | 174 | ||
| 1 Jan 2020 – 31 Dec 2020 | 189 | Late | |
| 1 Jan 2019 – 31 Dec 2019 | 231 | Late | |
| 1 Jan 2018 – 31 Dec 2018 | 151 | ||
| 22 Jun 2017 – 31 Dec 2017 | 142 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| Board | João Carlos Ribas de Almeida | Current | |
| Board | Gabor Gyulveszi | Current | |
| Board | Stephan Christgau | ||
| Board | Emmanuelle Coutanceau | ||
| Board | Emmanuelle Coutanceau | ||
| Board | Pieter Jeroen Bakker | ||
| Board | Morten Døssing | ||
| Board | João Carlos Ribas de Almeida | ||
| Owner (100%) | Novo Holdings A/S | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Novo Holdings A/S | Current |
Address history (1 moves)
| c/o Symbion, Nordre Fasanvej 215, 2000 Frederiksberg | |
| Ole Maaløes Vej 3, 2200 København N |
Former names
| de novo foundry ApS | – now |
| BiOrigin ApS | – |
| Bio Origin ApS | – |
Employees per year
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- RR Entreprise & Rådgivning ApS Frederiksberg
- DJTILBUD ApS Frederiksberg C
- CSTRL Group ApS Frederiksberg
- Future Consult ApS Frederiksberg
- Green Alchemy ApS Frederiksberg C
- Sun-Sun ApS Frederiksberg C
- Ascolta Artists ApS Frederiksberg
- DrugWise Discovery ApS Frederiksberg
- Modberg K ApS Frederiksberg
- MELLEM ApS Frederiksberg
- TECHR ApS Frederiksberg
- Inovia ApS Frederiksberg
Questions and answers about de novo foundry ApS
Has de novo foundry ApS gone bankrupt?
No, de novo foundry ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of de novo foundry ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the auditor of de novo foundry ApS?
de novo foundry ApS most recently used EY Godkendt Revisionspartnerselskab.
When was de novo foundry ApS founded?
de novo foundry ApS was founded on 22 June 2017.
What is the equity of de novo foundry ApS?
Equity was DKK 16.7m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.